161 related articles for article (PubMed ID: 28939070)
21. Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data.
Santa Cruz O; Tsoutsou P; Castella C; Khanfir K; Anchisi S; Bouayed S; Matzinger O; Ozsahin M
Oncology; 2018; 95(2):61-68. PubMed ID: 29895020
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
23. Predictors of toxicity after curative reirradiation with intensity modulated radiotherapy or proton therapy for recurrent head and neck carcinoma: new dose constraints for pharyngeal constrictors muscles and oral cavity.
Beddok A; Maynadier X; Krhili S; Ala Eddine C; Champion L; Chilles A; Goudjil F; Zefkili S; Amessis M; Choussy O; Le Tourneau C; Buvat I; Créhange G; Carton M; Calugaru V
Strahlenther Onkol; 2023 Oct; 199(10):901-909. PubMed ID: 37256301
[TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
Rastogi M; Sapru S; Gupta P; Gandhi AK; Mishra SP; Srivastava AK; Khurana R; Hadi R; Sahni K; S F
Oral Oncol; 2017 Apr; 67():10-16. PubMed ID: 28351562
[TBL] [Abstract][Full Text] [Related]
25. Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy.
McDonald MW; Liu Y; Moore MG; Johnstone PA
Radiat Oncol; 2016 Feb; 11():32. PubMed ID: 26922239
[TBL] [Abstract][Full Text] [Related]
26. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
[TBL] [Abstract][Full Text] [Related]
27. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
28. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
29. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
[TBL] [Abstract][Full Text] [Related]
30. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
[TBL] [Abstract][Full Text] [Related]
31. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
32. Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience.
Katsoulakis E; Riaz N; Hu M; Morris L; Sherman E; McBride S; Lee N
Laryngoscope; 2016 Mar; 126(3):620-6. PubMed ID: 26597398
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Lee A; Woods R; Mahfouz A; Kitpanit S; Cartano O; Mohamed N; Youssef I; Marqueen K; Sine K; Mah D; Neal B; Zakeri K; Kang JJ; Riaz N; Yu Y; McBride SM; Chen LD; Tsai CJ; Gelblum DY; Press RH; Michel LS; Sherman EJ; Pfister D; Dunn LA; Ho AL; Fetten J; Wong RJ; Boyle JO; Singh B; Cracchiolo JR; Ganly I; Cohen MA; Lee NY
JAMA Netw Open; 2023 Jan; 6(1):e2250607. PubMed ID: 36689229
[TBL] [Abstract][Full Text] [Related]
34. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric predictors of dysphonia after intensity-modulated radiotherapy for oropharyngeal carcinoma.
Sanguineti G; Ricchetti F; McNutt T; Wu B; Fiorino C
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):32-8. PubMed ID: 23992739
[TBL] [Abstract][Full Text] [Related]
36. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.
Vlacich G; Stavas MJ; Pendyala P; Chen SC; Shyr Y; Cmelak AJ
Radiat Oncol; 2017 Jan; 12(1):13. PubMed ID: 28086954
[TBL] [Abstract][Full Text] [Related]
37. Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial.
Held T; Lang K; Regnery S; Weusthof K; Hommertgen A; Jäkel C; Tonndorf-Martini E; Krisam J; Plinkert P; Zaoui K; Freudlsperger C; Moratin J; Krauss J; Harrabi SB; Herfarth K; Debus J; Adeberg S
Radiat Oncol; 2020 Aug; 15(1):190. PubMed ID: 32758267
[TBL] [Abstract][Full Text] [Related]
38. Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity.
Nuyts S; Lambrecht M; Duprez F; Daisne JF; Van Gestel D; Van den Weyngaert D; Platteaux N; Geussens Y; Voordeckers M; Madani I; De Neve W
Radiother Oncol; 2013 Nov; 109(2):323-9. PubMed ID: 23953410
[TBL] [Abstract][Full Text] [Related]
39. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
40. Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach, part II: radiation technique and fractionations.
Alterio D; Zaffaroni M; Bossi P; Dionisi F; Elicin O; Falzone A; Ferrari A; Jereczek-Fossa BA; Sanguineti G; Szturz P; Volpe S; Scricciolo M
Radiol Med; 2023 Aug; 128(8):1007-1021. PubMed ID: 37415056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
